Skip to content

Psilocybin may be effective for treatment-resistant depression

Pharmaceutical journal/˜The œpharmaceutical journal 2022 DOI: 10.1211/pj.2022.1.164911 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Phase II trial Peer reviewed
Population People with treatment-resistant depression
Intervention Psilocybin
Dose 25 mg
Topics Depression Psilocybin
Keywords Depression economics Psychotherapist Hallucinogen Keynesian economics
Key findings A single 25mg dose of psilocybin with psychological support may improve symptoms of treatment-resistant depression.

Abstract

The largest trial to date of the psychedelic drug psilocybin has shown that, alongside psychological support, a single 25mg dose may improve the symptoms of treatment-resistant depression. The phase II study, published in the New England Journal of Medicine on 3 November 2022, was conducted across 22 sites in 10 countries, including the UK, between […]

Comparable studies

Other non-randomized and open-label trials on psilocybin for depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Patients with major depressive disorder 2021 Open-label study n = 24
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Individuals diagnosed with moderate to severe, treatment-resistant depression 2017 Open-label study n = 20

Related reading

Explore topics

Depression Psilocybin

By condition and practice

Psilocybin for depression